Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults


Brief Summary

This study evaluates safety, tolerability and immunogenicity of two doses of GHB04L1, a liquid formulation of the replication- deficient influenza A/Vietnam/1203/04(H5N1)-like ∆NS1 virus in healthy adults. Subjects are randomised at a ratio of 2:1 for GHB04L1 (6.8 log10 or 7.5 log10 TCID50/dose/volunteer) or placebo.

Intervention / Treatment

  • Placebo (OTHER)
    Buffer solution

Condition or Disease

  • Influenza, Avian


  • Phase 1
  • Study Design

    Study type: INTERVENTIONAL
    Status: Completed
    Study results: No Results Available
    Age: 18 Years to 50 Years
    Enrollment: 36 (ACTUAL)
    Funded by: Industry
    Allocation: Randomized
    Primary Purpose: Prevention


    • Participant
    • Investigator

    Clinical Trial Dates

    Start date: Dec 19, 2008 ACTUAL
    Primary Completion: May 27, 2009 ACTUAL
    Completion Date: May 27, 2009 ACTUAL
    Study First Posted: Nov 19, 2018 ACTUAL
    Last Updated: Nov 18, 2018

    Sponsors / Collaborators

    Lead sponsor is responsible party
    Responsible Party: N/A

    GHB04L1 is intended to provide a novel treatment approach for influenza virus H5N1 infection. Based on preclinical data from ferrets that demonstrated protection against challenge with wild-type virus following treatment with various dose levels of GHB04L1, vaccination with GHB04L1 might protect humans from influenza A (H5N1) virus infection.

    Due to the lack of the NS1 protein, the ΔNS1 virus replicates efficiently in interferon-deficient cells but has lost its ability to grow in normal hosts and organisms. Immunisation with ΔNS1 mutant virus can cause only an abortive replication cycle in the nasal mucosa of vaccinated individuals. This allows development of replication-deficient intranasal vaccines with genetic stability of the attenuated phenotype and without virus shedding.

    Participant Groups

    • GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.

    • Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.

    Eligibility Criteria

    Sex: All
    Minimum Age: 18
    Maximum Age: 50
    Age Groups: Adult
    Healthy Volunteers: Yes

    Inclusion Criteria:

    * Male or female healthy volunteers, 18-50 years of age
    * Seronegative for H5N1 (with antibody titres \<1:10 detected in HAI assay)
    * Seronegative for H1N1 (with antibody titres ≤1:20 detected in HAI assay)
    * Written informed consent to participate in this study

    Exclusion Criteria:

    * Acute febrile illness (\>37.0°C)
    * Positive influenza immunoassay at baseline
    * Signs of acute or chronic upper or lower respiratory tract illnesses (sneezing, cough, tonsillitis, otitis, etc.)
    * History of severe atopy
    * Influenza vaccination 2006/2007 and/or later
    * Known increased tendency of nose bleeding
    * Volunteers with clinically relevant abnormal paranasal anatomy
    * Volunteers with clinically relevant abnormal laboratory values Females with positive urine pregnancy test prior to vaccination
    * Simultaneous treatment with immunosuppressive drugs incl. corticosteroids (≥ 2 weeks) within 4 weeks prior to study medication application
    * Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases
    * History of leukaemia or cancer
    * HIV or hepatitis B or C seropositivity
    * Volunteers who had undergone rhino or sinus surgery or surgery of another traumatic injury of the nose within 30 days prior to application of study medication
    * Volunteers who had received antiviral drugs, treatment with immunoglobulins or blood transfusions or an investigational drug within four weeks prior to study medication application
    * Volunteers who had received anti-inflammatory drugs 2 days prior to study medication application
    * Volunteers who were not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

    Primary Outcomes
    • Occurrence of local and systemic adverse events overall and within 7 days after each study medication administration

    Secondary Outcomes
    • Presence of GHB04L1 in mucosal samples from the nose

    • Local influenza A virus-specific immune response (IgA) in mucosal samples from the nose

    • Local cytokines response in mucosal samples from the nose

    • Systemic influenza A virus-specific antibody response determined by haemagglutination-inhibition assay (HAI) and micro-neutralisation assay (MNA) in serum samples

    • Systemic influenza A virus-specific T-cell response determined by T-cell proliferation assay in blood samples

    • Systemic natural killer cell cytotoxicity in blood samples

    • Systemic T-cell Granzyme B assay in blood samples

    More Details

    NCT Number: NCT03745274
    Other IDs: GHB-CS02
    Study URL:
    Last updated: Sep 29, 2023